DAXOR
New York
About DAXOR
DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $22.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nysemkt:DXR
- Website: daxor.com
- Phone: 2122440806
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/daxor-74228 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.